Full text: Unavailable
Although systemic treatments are warranted in aggressive forms of classic and endemic Kaposi sarcomas (KS), therapeutic guidelines are lacking for those nonimmunodeficient subtypes. In this retrospective multicentre study, we showed that paclitaxel, liposomal doxorubicin and low-dose interferon had good overall response rates for nonimmunodeficient KS with acceptable tolerance profiles. In addition, we highlighted the aggressiveness of endemic KS compared with classic KS with a higher risk of dissemination and response depletion as progression proceeded.